Jinwon Life Sciences Completes First Subject Vaccination in COVID-19 Vaccine Clinical Trial

[Asia Economy Reporter Jang Hyowon] On the 4th, GeneOne Life Science announced that on the 31st, it completed the vaccination of the first subject in the Phase 1/2a clinical trial of GLS-5310, a novel coronavirus disease (COVID-19) vaccine, at Korea University Guro Hospital.

A company official stated, “After receiving approval for the clinical trial plan from the Ministry of Food and Drug Safety on the 4th of last month, we quickly prepared for the clinical trial, obtained IRB approval from Korea University Guro Hospital on the 14th, and on the 31st completed the first vaccination for six clinical trial subjects, officially commencing the Phase 1 clinical trial.”

GeneOne Life Science said, “The Phase 1 clinical trial of GLS-5310 targets 45 healthy adults to evaluate the safety, optimal dosage, and dosing interval of GLS-5310. The upcoming Phase 2a clinical trial will be conducted on 300 healthy adults using a placebo-controlled, double-blind design to assess the safety and immunogenicity of GLS-5310. The trial will be carried out at five clinical institutions, including Korea University Guro Hospital.”

Park Young-geun, CEO of GeneOne Life Science, said, “Although it is a busy time at the end of the year, with the cooperation of Korea University Guro Hospital, we have successfully completed the first vaccination of the first subject for the COVID-19 vaccine GLS-5310. We will focus on completing the registration and first vaccination of all clinical trial subjects in the Phase 1 clinical trial by the end of this month to rapidly develop the vaccine.”

This content was produced with the assistance of AI translation services.